LitPRO
Until 2020, Zantac was a popular brand name of the drug ranitidine and was widely used to treat heartburn and acid reflux. At higher dosages, Zantac was also prescribed for treatment of stomach ulcers and erosive esophagitis. Zantac was first sold in the U.S. in 1983 and quickly became one of the most widely used drugs on the market.
In 2019, manufacturer Sanofi announced a voluntary recall of Zantac because it contained N-Nitrosodimethylamine (NDMA), which may cause cancer in humans. In 2020, the Food and Drug Administration (FDA) asked that all forms of ranitidine products be pulled from the market. Zantac is no longer available in prescription or over the counter (OTC) forms.
Lawsuits have been filed by Zantac users who developed cancer thought to have been caused by the presence of NDMA in the medication. Lawsuits also claim that the manufacturer did not warn them about the drug’s risks.
Potential Zantac-related injuries may include cancers of the stomach, bladder, kidney, pancreas, colon, liver, esophagus, lung, or breast. Plaintiffs in this litigation have all kinds of healthcare insurance, so any type of healthcare lien may result from a settlement.
